Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor-targeted Therapy.
Zakaria ChakraniGeorge MellgardNathaniel SaffranStephen McCroskeryNicole TaylorMann PatelBobby LiawMatthew GalskyWilliam K OhChe-Kai TsaoVaibhav G PatelPublished in: American journal of clinical oncology (2024)
Our work presents the first description of ART treatment discontinuation and its causes in the real-world setting, as well as patient-reported side effects. Most patients with mCRPC discontinued treatment due to the progression of disease and a minority of patients discontinued secondary to treatment toxicity. Initial multivariable analysis suggests that patient-reported weakness, falls, and rash were associated with a higher likelihood of treatment discontinuation due to toxicity. Early monitoring of this population can prolong the duration of treatment and prevent unnecessary treatment burden.